The Neutral rating from HC Wainwright & Co. analyst Raghuram Selvaraju indicates that the analyst does not see any significant short-term price movement for Oncternal Therapeutics. This rating suggests that the stock is fairly valued and there is no strong catalyst for price change in the near future. As a result, the short-term impact on the stock price is neutral.